{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:19:26Z","timestamp":1787840366156,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"\n Context:<\/jats:title>\n Central nervous system tumors are a major cause of morbidity and mortality worldwide. The most prevalent type of primary brain tumor is glioma. The exploration of significant genetic, epigenetic, and transcriptional abnormalities has not only improved our understanding of glioma pathogenesis but has also revealed that these molecular alterations can serve as useful diagnostic markers for more precise classification and are linked to better treatment response and prognosis. Hence, incorporating molecular markers into routine tumor classification is a major priority in modern glioma diagnostics.<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n The aim is to assess the mutation status of isocitrate dehydrogenase (IDH)-1, alpha-thalassemia\/mental retardation syndrome X-linked (ATRX), and tumor protein 53 in glioma, and look for their association with various clinicopathological features.<\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n A single-center prospective cohort study, where all biopsies of glioma (January 2019 to July 2020) were evaluated, and immunohistochemistry was performed to assess the expression of IDH-1, ATRX, p53, and Ki-67 index. The data were analyzed using IBM SPSS-24 software.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Immunohistochemistry was performed in 123 consecutive cases of glioma. IDH-1 mutation was noted in 54 (43.9%) cases and these patients frequently presented with \u201cseizures\u201d (\n P<\/jats:italic>\n = 0.006). The expression was maximum in World Health Organization (WHO) grade 2 tumors (65.4%) (\n P<\/jats:italic>\n < 0.001), with the highest frequency in oligodendrogliomas (100% in WHO grade 2 and 3). Furthermore, these tumors showed lower proliferative indices (\n P<\/jats:italic>\n = 0.001). ATRX mutation was noted in 59 (48%) and p53 overexpression was noted in 76 (61.8%) cases. These mutations were significantly associated with astrocytic phenotype (\n P<\/jats:italic>\n = 0.03).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Molecular characterization of glioma is an important step in modern glioma diagnostics and immunohistochemistry can play an important role. IDH-1 mutation is commonly observed in adults, frontal lobe location, patients presenting with seizures, and WHO grade 2 tumors with the highest frequencies in oligodendrogliomas. ATRX and p53 can be used as surrogate markers for tumors of astrocytic lineage.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/aam.aam_127_23","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T07:04:09Z","timestamp":1731049449000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Study of Molecular Markers in Glioma and Their Association with Clinicopathological Features"],"prefix":"10.4103","volume":"24","author":[{"given":"Alka","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awadhesh Kumar","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"R1-20260427","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1474-4422(18)30468-X","article-title":"Global, regional, and national burden of brain and other CNS cancer, 1990\u20132016: A systematic analysis for the global burden of disease study 2016","volume":"18","author":"Patel","year":"2019","journal-title":"Lancet Neurol"},{"key":"R2-20260427","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/2278-330X.187589","article-title":"Indian data on central nervous tumors: A summary of published work","volume":"5","author":"Dasgupta","year":"2016","journal-title":"South Asian J Cancer"},{"key":"R3-20260427","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev-pathol-121808-102109","article-title":"The pathobiology of glioma tumors","volume":"5","author":"Gladson","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"R4-20260427","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/B978-0-12-802997-8.00006-2","article-title":"Molecular classification of gliomas","volume":"134","author":"Masui","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"R5-20260427","first-page":"343","article-title":"Clinical relevance of molecular markers in gliomas","volume":"28","author":"Monga","year":"2017","journal-title":"Las Condes Clin Med J"},{"key":"R6-20260427","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1215\/15228517-2009-025","article-title":"IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas","volume":"11","author":"Ichimura","year":"2009","journal-title":"Neuro Oncol"},{"key":"R7-20260427","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.7150\/jca.38603","article-title":"Practice of the new integrated molecular diagnostics in gliomas: Experiences and new findings in a single Chinese center","volume":"11","author":"Hu","year":"2020","journal-title":"J Cancer"},{"key":"R8-20260427","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/jclinpath-2017-204638","article-title":"A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up","volume":"71","author":"Rajeswarie","year":"2018","journal-title":"J Clin Pathol"},{"key":"R9-20260427","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe","year":"2009","journal-title":"Am J Pathol"},{"key":"R10-20260427","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yexmp.2011.04.017","article-title":"IDH1 mutations in gliomas: First series from a tertiary care Centre in India with comprehensive review of literature","volume":"91","author":"Jha","year":"2011","journal-title":"Exp Mol Pathol"},{"key":"R11-20260427","doi-asserted-by":"crossref","first-page":"345.","DOI":"10.1007\/s11910-013-0345-4","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"13","author":"Cohen","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R12-20260427","doi-asserted-by":"crossref","first-page":"A522","DOI":"10.21276\/APALM.1458","article-title":"Immunohistochemical expression of IDH1R132H in astrocytic tumours and its association with histopathological grade, TP53 and EGFR protein expression","volume":"4","author":"Mishra","year":"2017","journal-title":"Ann Pathol Lab Med"},{"key":"R13-20260427","doi-asserted-by":"crossref","first-page":"29.","DOI":"10.4103\/sni.sni_284_17","article-title":"IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in North Indian population","volume":"9","author":"Chatterjee","year":"2018","journal-title":"Surg Neurol Int"},{"key":"R14-20260427","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.18203\/2349-2902.isj20203792","article-title":"A single-Centre observational study of 124 surgically managed glioma patients: Molecular subtyping and its correlation with clinico-radiological profile","volume":"7","author":"Singh","year":"2020","journal-title":"Int Surg J"},{"key":"R15-20260427","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/0973-1482.106567","article-title":"Immunohistochemical expression of IDH1 in gliomas: A tissue microarray-based approach","volume":"8","author":"Sipayya","year":"2012","journal-title":"J Cancer Res Ther"},{"key":"R16-20260427","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00381-010-1264-1","article-title":"IDH1 mutations are common in malignant gliomas arising in adolescents: A report from the children\u2019s oncology group","volume":"27","author":"Pollack","year":"2011","journal-title":"Childs Nerv Syst"},{"key":"R17-20260427","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/humu.20937","article-title":"IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors","volume":"30","author":"Bleeker","year":"2009","journal-title":"Hum Mutat"},{"key":"R18-20260427","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00432-013-1519-9","article-title":"Correlation of IDH1\/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: A report of 203 patients from China","volume":"140","author":"Zhang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"R19-20260427","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10014-014-0211-3","article-title":"Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas","volume":"32","author":"Sonoda","year":"2015","journal-title":"Brain Tumor Pathol"},{"key":"R20-20260427","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/neup.12608","article-title":"Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing","volume":"40","author":"Barresi","year":"2020","journal-title":"Neuropathology"},{"key":"R21-20260427","doi-asserted-by":"crossref","first-page":"30232","DOI":"10.18632\/oncotarget.4920","article-title":"IDH1\/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma","volume":"6","author":"Zeng","year":"2015","journal-title":"Oncotarget"},{"key":"R22-20260427","doi-asserted-by":"crossref","first-page":"e30339.","DOI":"10.1371\/journal.pone.0030339","article-title":"Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: A report of 118 patients from China","volume":"7","author":"Yan","year":"2012","journal-title":"PLoS One"},{"key":"R23-20260427","first-page":"127","article-title":"Alterations in TP53 gene\u2013Implications in tumorigenesis. Process and prognosis in central nervous system cancer","author":"Pess\u00f4a","year":"2014","journal-title":"Tumors of the Central Nervous System-Primary and Secondary"},{"key":"R24-20260427","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4103\/ijmr.IJMR_1179_15","article-title":"Expression of p53 and epidermal growth factor receptor in glioblastoma","volume":"146","author":"Karnam","year":"2017","journal-title":"Indian J Med Res"},{"key":"R25-20260427","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00401-013-1156-z","article-title":"ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis","volume":"126","author":"Wiestler","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R26-20260427","doi-asserted-by":"crossref","first-page":"794.","DOI":"10.3390\/cancers11060794","article-title":"Oncogenic BRAF alterations and their role in brain tumors","volume":"11","author":"Behling","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R27-20260427","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.18632\/oncotarget.689","article-title":"Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma","volume":"3","author":"Kannan","year":"2012","journal-title":"Oncotarget"},{"key":"R28-20260427","first-page":"131","article-title":"TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas","volume":"118","author":"Gillet","year":"2014","journal-title":"J Neurooncol"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_127_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:21:28Z","timestamp":1787836888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_127_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_127_23","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"2023-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}